Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer

Murray K., Oldfield L., Stefanova I., Gentiluomo M., Aretini P., O'Sullivan R., ...More

Seminars in Cancer Biology, vol.111, pp.76-88, 2025 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Review
  • Volume: 111
  • Publication Date: 2025
  • Doi Number: 10.1016/j.semcancer.2025.02.009
  • Journal Name: Seminars in Cancer Biology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, MEDLINE
  • Page Numbers: pp.76-88
  • Keywords: Artificial intelligence, Biomarkers, Early detection, Omics, Pancreatic cancer
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.